Micafungin Teva

Micafungin, the active ingredient in Micafungin Teva, is an echinocandin antifungal presented as an intravenous solution for infusion use. It treats invasive Candida infections and is used in immunocompromised patients such as those undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungin Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Micafungin is an echinocandin antifungal used to manage serious Candida infections and to prevent infection in high‑risk patients.

- Invasive candidiasis: treatment of bloodstream and deep‑tissue Candida infections in adult and pediatric patients. - Candida esophagitis: eradication of fungal infection of the esophagus caused by Candida species. - Candida peritonitis: management of intra‑abdominal Candida infection, especially in postoperative settings. - Prophylaxis in hematopoietic stem cell transplantation: prevention of Candida infection in patients receiving stem‑cell transplants.

Micafungin may cause a range of adverse reactions, from mild to severe. Monitoring and prompt reporting of symptoms are recommended.

Common Side Effects: - Fever: transient elevation of body temperature during infusion. - Phlebitis: irritation at the intravenous site. - Elevated liver enzymes: mild increases in ALT or AST. - Nausea: occasional gastrointestinal discomfort. - Headache: mild to moderate intensity. - Rash: skin redness or mild itching.

Serious or Rare Side Effects: - Severe hepatic dysfunction: marked liver enzyme elevation or hepatitis. - Hypersensitivity reactions: including anaphylaxis. - Stevens‑Johnson syndrome: severe skin and mucosal reactions. - Renal failure: acute kidney injury in susceptible patients. - Severe neutropenia: marked reduction in neutrophil count. - Hemodynamic instability: hypotension during rapid infusion.

Before using Micafungin, clinicians should consider several safety measures.

- Renal function: assess and monitor in patients with impaired kidney function. - Hepatic function: evaluate baseline liver enzymes and monitor during therapy. - Concomitant medications: review for potential interactions that may affect micafungin levels. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Storage: Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other drugs, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Cyclosporine: may increase micafungin exposure, risking toxicity. - Rifampin: may decrease micafungin plasma concentrations, reducing effectiveness. - Co‑administration with other echinocandins: avoid duplication of antifungal class.

Moderate Interactions (Monitor Closely): - Azole antifungals: potential additive hepatotoxicity; monitor liver function. - Immunosuppressants (e.g., tacrolimus): monitor drug levels for possible alterations. - Warfarin: may affect INR; regular coagulation monitoring is advised.